Skip to Main Content

Paper Details

Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors.
J Immunother Cancer
14
2022
Author NameAffiliation
Wei YuanInstitute of Cancer Research
Malaka AmeratungaRoyal Marsden Hospital/Institute of Cancer Research
Susana MirandaInstitute of Cancer Research
Suzanne CarreiraInstitute of Cancer Research
Robert BrownImperial College London
Nina TunariuRoyal Marsden Hospital/Institute of Cancer Research
Johann S de BonoInstitute of Cancer Research
Johann S de BonoRoyal Marsden Hospital/Institute of Cancer Research
  • 1 - 8

Datasets

Release 1.2